Hims & Hers Health is an e-commerce company selling commoditized generic medications at massive premiums, structured to generate high-volume prescriptions rather than provide credible healthcare services.
Despite blistering 88% revenue CAGR since 2020, Spruce Point alleges the Company operates its physician network on shaky legal ground vis-à-vis Corporate Practice of Medicine provisions, faces existential risk from OTC ED alternatives, has failed to deliver on virtually every growth initiative, and misrepresents core business metrics including customer churn and acquisition costs.
CPoM Violations
HIMS' "Friendly PC" structure may violate Corporate Practice of Medicine provisions. Physician "owners" are figureheads with no equity, voting rights, or financial claims. HIMS controls medical practice despite regulatory disclosures claiming otherwise.
OTC ED Threat
FDA-approved OTC ED treatment Eroxon eliminates the need for a HIMS prescription in a category estimated at over 50% of revenue. Core revenue model fundamentally threatened.
Dubious Care Model
Average consultations estimated at under 5 minutes. Mostly asynchronous, check-the-box affairs. Founding medical director received disciplinary action for "gross negligence" before co-founding troubled Cerebral.
Supply Chain Exposure
Key pharmacy partner Truepill faces DEA investigation. ITC Compounding forced to shut down by FDA. Curexa received three FDA inspection letters. Fareva hit with EPA violations.
Churn Misrepresented
Spruce Point estimates over 50% of customers churn by year 1 and nearly 80% by year 2. HIMS deflects by quoting a "long-term retention rate" that only captures year 2 to year 3 performance.
Failed Growth Initiatives
Health system partnerships with no economic substance. Abandoned insurance market pursuit. Enterprise offering vanished. International inflated. Wholesale revenue turned negative. Women's platform poorly rated.
The "Friendly PC" Structure Spruce Point Believes Is On Shaky Ground
HIMS (NYSE: HIMS)
→
H&H Healthcare Mgmt (MSO)
→
Affiliated Medical Groups
(Bailey → You Health → Human Health)
(Bailey → You Health → Human Health)
Admin fees flow up · "Exclusive medical authority" claimed by AMGs · HIMS' own accounting disclosures contradict this claim
2 Physician "Owners"
Williams & Powell manage 600+ docs
Williams & Powell manage 600+ docs
→
1099 Contractor Physicians
Part-time, non-exclusive, high turnover
Part-time, non-exclusive, high turnover
→
Customers / Patients
Primarily young men seeking ED pills
Primarily young men seeking ED pills
Restrictive stock transfer agreements give HIMS effective control · Physicians have zero equity or voting rights
Spruce Point Estimated Cumulative Customer Churn
HIMS Premium Pricing vs. Competitor Alternatives
| Pharmacy Partner | Status | Key Issue |
|---|---|---|
| Truepill (PostMeds) | ✗ Under Investigation | DEA Order to Show Cause for unlawful dispensing of controlled substances; mass layoffs |
| ITC Compounding | ✗ Facility Shutdown | FDA inspection found violations "injurious to health"; forced temporary facility closure |
| Curexa (EHT Pharmacy) | ✗ 3 FDA Letters | Below-strength products, sloppy operations, facility structural concerns across three inspections |
| Fareva | ✗ EPA Violations | Virginia air violation (Jan 2023) and EPA civil enforcement order (2021) for hazardous waste |
| Apostrophe (In-house) | ✗ Limited Capacity | Contracts with both ITC and Truepill; modest internal capabilities; not FDA-registered |
On Physician Ownership
"I wish...no, none of that. There was no equity in the PC. The PC was basically worthless from a financial perspective. In practicality, the PC owner really doesn't do anything. It's just kind of a figurehead."
— Former HIMS Physician
On HIMS as a Healthcare Company
"There's a fundamental lack of healthcare expertise, like really fundamental deep healthcare expertise. I'd say that three people at HIMS had real healthcare expertise, but no one seemed really interested in any of their input."
— Former HIMS Executive
On Prescription-Driven Metrics
"Those success metrics are around number of prescriptions. Providers exist to prescribe first, which means they're looking for symptoms and then prescribing, which leads to horribly misaligned incentives."
— Former HIMS Executive
On The Target Customer
"Their customer is the 25 to 35 year old that drinks too much on the weekends and still wants to be able to perform. I know that really sounds tongue in cheek, but that is the customer."
— Former HIMS Executive
| Initiative | Status | Outcome |
|---|---|---|
| Health System Partnerships | ✗ No Substance | Ochsner, Mount Sinai, Privia, Carbon Health deals have no economic substance; marketing puffery |
| Insurance Market Entry | ✗ Abandoned | After two years of investor guidance, HIMS acknowledged it will not pursue insured customers |
| HIMS for Enterprise | ✗ Vanished | Pitched in SPAC presentation; never mentioned again in subsequent filings or calls |
| International Expansion | ✗ Inflated | Tiny UK acquisition grossly overstated; no coherent strategy for different regulatory landscapes |
| Wholesale / Retail | ✗ Declining | Despite Target, Walmart, GNC puffery — wholesale revenue growth turned negative |
| Women's Health (Hers) | ✗ Poor Reviews | 78% 1-star ratings on Trustpilot vs. 14% for Hims; platform ill-suited for women's conditions |
| In-house Pharmacy (100%) | ✗ Missed Target | Promised 100% by YE 2022; only reached ~60% by Q1 2023 with 80% goal for YE 2023 |